The first GLP-1 drug, exenatide, was approved back in 2005 when I was in pharmacy school
The SURPASS-CVOT trial, where dulaglutide at the dose of 1.5 mg/week or at the highest tolerated dose, is the comparator, has a distinctive design from the other trials: the primary endpoint is the time to the first manifestation of any major adverse CV event (MACE), defined as myocardial infarction, stroke or CV death
What the Research Shows So Far BPC-157 has been studied for over two decades in animal models and preclinical studies, with consistent findings across a wide range of tissues and systems: BPC-157 has shown an extremely high safety margin in rodents, with no toxicity or organ damage reported even at doses much higher than those typically used in humans. Sikiric, P
A single molecule activates three receptors at once: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon (GCGR)
Lets get you answers to some of the most common questions